- Edwards Lifesciences recently reported new two-year TRISCEND II data at ACC.26 showing its EVOQUE transcatheter tricuspid valve replacement system nearly eliminated tricuspid regurgitation, improved quality of life, and was associated with lower all-cause mortality without added device-related risk in severe tricuspid regurgitation patients.
- This growing body of evidence, now spanning randomized trials and real-world registry data in more than 1,000 patients across the US and Europe, reinforces EVOQUE’s role as a comprehensive therapy option for a previously under-treated valve disease.
- We’ll now examine how EVOQUE’s sustained mortality and quality-of-life benefits could influence Edwards Lifesciences’ long-term investment narrative and growth outlook.
Find 62 companies with promising cash flow potential yet trading below their fair value.
Edwards Lifesciences Investment Narrative Recap
To own Edwards Lifesciences, you need to believe that its transcatheter structural heart portfolio can translate strong clinical data into durable procedure volumes and earnings, despite competitive and cost pressures. The new two year TRISCEND II EVOQUE data supports the tricuspid opportunity and aligns with Edwards’ broader transcatheter thesis, but does not materially change the nearer term focus on executing TAVR growth and managing rising operating expenses as the key catalyst and risk.
The most relevant recent announcement alongside the EVOQUE data is Edwards’ 2026 guidance, which targets sales growth of 8% to 10% and EPS of US$2.90 to US$3.05. These figures assume the company can absorb tariff headwinds and JenaValve related EPS dilution while funding high discretionary R&D, so investors will likely watch how EVOQUE and other new therapies contribute to offsetting these cost and margin pressures over time.
Yet against this innovation story, investors should also be aware that tariff related margin pressure could...
Read the full narrative on Edwards Lifesciences (it's free!)
Edwards Lifesciences' narrative projects $8.1 billion revenue and $2.0 billion earnings by 2029. This requires 9.9% yearly revenue growth and about a $0.9 billion earnings increase from $1.1 billion today.
Uncover how Edwards Lifesciences' forecasts yield a $96.93 fair value, a 22% upside to its current price.
Exploring Other Perspectives
Three members of the Simply Wall St Community currently see Edwards’ fair value between US$88.35 and US$96.93, underscoring how widely opinions can differ. You can weigh those views against the catalyst of expanding TAVR and tricuspid indications, which could meaningfully affect how the business absorbs rising R&D and tariff related costs.
Explore 3 other fair value estimates on Edwards Lifesciences - why the stock might be worth just $88.35!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Edwards Lifesciences research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Edwards Lifesciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Edwards Lifesciences' overall financial health at a glance.
Curious About Other Options?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
- AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Outshine the giants: these 20 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com